Bruker Corp BRKR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BRKR is a good fit for your portfolio.
News
-
Accelerate Diagnostics Announces Collaboration for the Use of the Arc™ System in Combination With Bruker´s MALDI Biotyper®
-
Bruker Announces Quarterly Dividend
-
Bruker Corporation to Participate in the 2023 Jefferies London Healthcare Conference
-
Bruker Reports Third Quarter 2023 Financial Results
-
Bruker Announces Date and Time of Third Quarter 2023 Earnings Release and Webcast
-
Bruker Announces Majority Investment in MIRO Analytical AG, an Innovator in Compact, Highest-Precision QCL-Based Multi-Gas Analyzers (MGA)
-
Bruker Completes Acquisition of PhenomeX
-
Bruker Introduces Next-Generation Nanomechanical Test System
Trading Information
- Previous Close Price
- $65.80
- Day Range
- $66.00–68.16
- 52-Week Range
- $53.79–84.84
- Bid/Ask
- $67.68 / $68.34
- Market Cap
- $9.41 Bil
- Volume/Avg
- 1.2 Mil / 832,999
Key Statistics
- Price/Earnings (Normalized)
- 25.94
- Price/Sales
- 3.56
- Dividend Yield
- 0.29%
- Dividend Yield (Forward)
- 0.29%
- Total Yield
- 1.58%
Company Profile
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives a majority of its revenue from Europe.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 8,525
- Website
- https://www.bruker.com
Valuation
|
Metric
|
BRKR
|
|---|---|
Price/Earnings (Normalized) | 25.94 |
Price/Book Value | 8.20 |
Price/Sales | 3.56 |
Price/Cash Flow | 20.12 |
Price/Earnings
BRKR
Financial Strength
|
Metric
|
BRKR
|
|---|---|
Quick Ratio | 0.95 |
Current Ratio | 1.89 |
Interest Coverage | 26.56 |
Quick Ratio
BRKR
Profitability
|
Metric
|
BRKR
|
|---|---|
Return on Assets (Normalized) | 10.52% |
Return on Equity (Normalized) | 34.10% |
Return on Invested Capital (Normalized) | 16.53% |
Return on Assets
BRKR
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
ABT
| Abbott Laboratories | Skpfjy | $182.2 Bil | |
SYK
| Stryker Corp | Gpl | $109.4 Bil | |
MDT
| Medtronic PLC | Yck | $105.1 Bil | |
BSX
| Boston Scientific Corp | Qhwklw | $80.3 Bil | |
DXCM
| DexCom Inc | Hfyq | $45.0 Bil | |
EW
| Edwards Lifesciences Corp | Svltrn | $42.1 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Rzz | $24.3 Bil | |
PHG
| Koninklijke Philips NV ADR | Mtrxzqc | $18.5 Bil | |
ALGN
| Align Technology Inc | Tscbg | $16.6 Bil | |
PODD
| Insulet Corp | Gbhmnng | $13.2 Bil |